Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 2285-2297

  Lee, Young Seok ^a   Hwang, Sun Goo ^b   Kim, Jin Ki ^a   Park, Tae Hwan ^c   Kim, Young Rae ^a   Myeong, Ho Sung ^a   Choi, Jong Duck ^a   Kwon, Kang ^d   Jang, Cheol Seong ^b   Ro, Young Tae ^a   Noh, Yun Hee ^a   Kim, Sung Young ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Acquired lapatinib resistance; Breast cancer; Differentially expressed genes; Meta analysis; Microarray

Indexed keywords

LAPATINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST CANCER; CARCINOGENESIS; DOWN REGULATION; DRUG RESISTANCE; FHL2 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; LGALS1 GENE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PRSS23 GENE; PTRF GENE; SOCS2 GENE; TOB1 GENE; UPREGULATION; BREAST NEOPLASMS; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; META ANALYSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN INTERACTION MAPS; QUINAZOLINES;

EID: 84941346602     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4033-7     Document Type: Article

References (44)

1. Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv. 2013;31(8):1397–407. doi:10.1016/j.biotechadv.2013.06.004.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–34. doi:10.1038/nrd1984.
3. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 2012;18(7):1863–9. doi:10.1158/1078-0432.CCR-11-1590.
4. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–92. doi:10.1002/path.1706.
5. Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014;355:10–20. doi:10.1016/j.jtbi.2014.02.025.
6. Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics. 2009;3:289–301.
7. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31(Pt 2):2332–48. doi:10.1016/j.clinthera.2009.11.029.
8. Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol. 2007;18 Suppl 6:vi26–30. doi:10.1093/annonc/mdm220.
9. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426–47. doi:10.1016/j.clinthera.2008.08.008.
10. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.002.
11. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20(9):2249–56. doi:10.1158/1078-0432.CCR-13-1610.
12. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res. 2008;14(21):6730–4. doi:10.1158/1078-0432.CCR-08-0581.
13. Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83(8):1041–8. doi:10.1016/j.bcp.2011.12.025.
14. Wetterskog D, Shiu KK, Chong I, Meijer T, Mackay A, Lambros M, et al. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. Oncogene. 2014;33(8):966–76. doi:10.1038/onc.2013.41.
15. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259–70. doi:10.1016/j.ctrv.2013.09.002.
16. Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol. 2012;23(12):3007–16. doi:10.1093/annonc/mds200.
17. Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008;5(9), e184. doi:10.1371/journal.pmed.0050184.
18. Liu J, Li J, Li H, Li A, Liu B, Han L. A comprehensive analysis of candidate genes and pathways in pancreatic cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015;36(3):1849–57. doi:10.1007/s13277-014-2787-y.
19. Tulalamba W, Larbcharoensub N, Sirachainan E, Tantiwetrueangdet A, Janvilisri T. Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015. doi:10.1007/s13277-015-3268-7.
20. Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol. 2012;8:596. doi:10.1038/msb.2012.25.
21. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69(17):6871–8. doi:10.1158/0008-5472.CAN-08-4490.
22. Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, et al. NF-kappaB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. Mol Cancer Res. 2014;12(3):408–20. doi:10.1158/1541-7786.MCR-13-0206-T.
23. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7), e1000097. doi:10.1371/journal.pmed.1000097.
24. Xia J, Fjell CD, Mayer ML, Pena OM, Wishart DS, Hancock RE. INMEX—a web-based tool for integrative meta-analysis of expression data. Nucleic Acids Res. 2013;41(Web server issue):W63–70. doi:10.1093/nar/gkt338.
25. Fang F, Pan J, Xu L, Wang J. Identification of potential transcriptomic markers in developing ankylosing spondylitis: a meta-analysis of gene expression profiles. Biomed Res Int. 2015;2015:826316. doi:10.1155/2015/826316.
26. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–20. doi:10.1093/nar/gkq537.
27. Molina-Navarro MM, Trivino JC, Martinez-Dolz L, Lago F, Gonzalez-Juanatey JR, Portoles M, et al. Functional networks of nucleocytoplasmic transport-related genes differentiate ischemic and dilated cardiomyopathies. A new therapeutic opportunity. PLoS One. 2014;9(8), e104709. doi:10.1371/journal.pone.0104709.
28. Firoz A, Malik A, Singh SK, Jha V, Ali A. Comparative analysis of glycogene expression in different mouse tissues using RNA-Seq Data. Int J Genomics. 2014;2014:837365. doi:10.1155/2014/837365.
29. Gupta A, Schulze TG, Nagarajan V, Akula N, Corona W, Jiang XY, et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J. 2012;12(4):328–41. doi:10.1038/tpj.2011.9.
30. Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods. 2012;9(5):471–2. doi:10.1038/nmeth.1938.
31. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4, Article17. doi:10.2202/1544-6115.1128.
32. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. 2006;7 Suppl 1:S7. doi:10.1186/1471-2105-7-S1-S7.
33. Jiang J, Jia P, Zhao Z, Shen B. Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics. 2014;15:1015. doi:10.1186/1471-2164-15-1015.
34. Zhou X, Li D, Wang X, Zhang B, Zhu H, Zhao J, et al. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget. 2014.
35. Miao JH, Wang SQ, Zhang MH, Yu FB, Zhang L, Yu ZX, et al. Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway. Oncol Rep. 2014;32(4):1497–504. doi:10.3892/or.2014.3358.
36. Chan HS, Chang SJ, Wang TY, Ko HJ, Lin YC, Lin KT, et al. Serine protease PRSS23 is upregulated by estrogen receptor alpha and associated with proliferation of breast cancer cells. PLoS One. 2012;7(1), e30397. doi:10.1371/journal.pone.0030397.
37. Inder KL, Ruelcke JE, Petelin L, Moon H, Choi E, Rae J, et al. Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation. J Extracell Vesicles. 2014;3. doi:10.3402/jev.v3.23784.
38. Yi JS, Mun DG, Lee H, Park JS, Lee JW, Lee JS, et al. PTRF/cavin-1 is essential for multidrug resistance in cancer cells. J Proteome Res. 2013;12(2):605–14. doi:10.1021/pr300651m.
39. Xu J, Zhou J, Li MS, Ng CF, Ng YK, Lai PB, et al. Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells. PLoS One. 2014;9(8), e99359. doi:10.1371/journal.pone.0099359.
40. McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, et al. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. Cancer Res. 2013;73(16):5066–79. doi:10.1158/0008-5472.CAN-12-4520.
41. Jia S, Meng A. Tob genes in development and homeostasis. Dev Dyn. 2007;236(4):913–21. doi:10.1002/dvdy.21092.
42. O’Malley S, Su H, Zhang T, Ng C, Ge H, Tang CK. TOB suppresses breast cancer tumorigenesis. Int J Cancer. 2009;125(8):1805–13. doi:10.1002/ijc.24490.
43. Helms MW, Kemming D, Contag CH, Pospisil H, Bartkowiak K, Wang A, et al. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Cancer Res. 2009;69(12):5049–56. doi:10.1158/0008-5472.CAN-08-4154.
44. Iglesias-Gato D, Chuan YC, Wikstrom P, Augsten S, Jiang N, Niu Y, et al. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. 2014;35(1):24–33. doi:10.1093/carcin/bgt304.